{"id":"al-001","safety":{"commonSideEffects":[{"rate":"null","effect":"Increased risk of genital yeast infections"}]},"_chembl":{"chemblId":"CHEMBL4303484","moleculeType":"Small molecule","molecularWeight":"548.64"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting SGLT2, AL-001 reduces glucose reabsorption in the kidneys, thereby lowering blood glucose levels. This makes it a potential treatment for type 2 diabetes.","oneSentence":"AL-001 is a small molecule that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:20:35.584Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT04374136","phase":"PHASE3","title":"A Phase 3 Study to Evaluate Efficacy and Safety of AL001 in Frontotemporal Dementia (INFRONT-3)","status":"TERMINATED","sponsor":"Alector Inc.","startDate":"2020-07-23","conditions":"Frontotemporal Dementia","enrollment":119},{"nctId":"NCT06111014","phase":"PHASE3","title":"Continuation Study for Latozinemab","status":"TERMINATED","sponsor":"Alector Inc.","startDate":"2023-12-08","conditions":"Neurodegenerative Diseases","enrollment":17},{"nctId":"NCT06921590","phase":"PHASE1","title":"A Study to Investigate Lithium Brain/Plasma Pharmacokinetics and Safety of an AL001 Oral Capsule Compared to a Marketed Immediate-release Lithium Carbonate Capsule in Healthy Adult Subjects","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alzamend Neuro, Inc.","startDate":"2025-05-09","conditions":"Pharmacokinetics, Neurology","enrollment":6},{"nctId":"NCT03987295","phase":"PHASE2","title":"A Phase 2 Study to Evaluate Safety of Long-term AL001 Dosing in Frontotemporal Dementia (FTD) Patients (INFRONT-2)","status":"COMPLETED","sponsor":"Alector Inc.","startDate":"2019-09-27","conditions":"Frontotemporal Dementia","enrollment":33},{"nctId":"NCT05053035","phase":"PHASE2","title":"A Phase 2 Study to Evaluate AL001 in C9orf72-Associated ALS","status":"TERMINATED","sponsor":"Alector Inc.","startDate":"2021-09-02","conditions":"Amyotrophic Lateral Sclerosis","enrollment":5},{"nctId":"NCT05363293","phase":"PHASE1, PHASE2","title":"Multiple Ascending Dose Safety, Tolerability, PK Study of AL001 in Alzheimer's Disease Patients & Healthy Adult Subjects","status":"COMPLETED","sponsor":"Alzamend Neuro, Inc.","startDate":"2022-05-04","conditions":"Alzheimer's Disease, Healthy Non-elderly and Elderly Adults","enrollment":65},{"nctId":"NCT06707753","phase":"PHASE1, PHASE2","title":"Safety and Tolerability of AL-001 Ophthalmic Injection in Subjects with WAMD","status":"ACTIVE_NOT_RECRUITING","sponsor":"Beijing Anlong Biopharmaceutical Co., Ltd.","startDate":"2023-09-11","conditions":"Wet Age-related Macular Degeneration (wAMD)","enrollment":21},{"nctId":"NCT06839339","phase":"PHASE2","title":"Efficacy and Safety of AL-001 Ophthalmic Injection in Subjects with WAMD","status":"NOT_YET_RECRUITING","sponsor":"Beijing Anlong Biopharmaceutical Co., Ltd.","startDate":"2025-02-18","conditions":"Wet Age-related Macular Degeneration (wAMD)","enrollment":40},{"nctId":"NCT06718816","phase":"","title":"Long-term Follow-up Study of AL-001 Ophthalmic Injection in Subjects with WAMD","status":"RECRUITING","sponsor":"Beijing Anlong Biopharmaceutical Co., Ltd.","startDate":"2024-12-09","conditions":"Wet Age-related Macular Degeneration (wAMD)","enrollment":21},{"nctId":"NCT05817214","phase":"PHASE2","title":"Cadonilimab Plus Anlotinib for R/M/P Cervical Cancer","status":"RECRUITING","sponsor":"Zhongnan Hospital","startDate":"2023-02-16","conditions":"Cervical Cancer","enrollment":35},{"nctId":"NCT03636204","phase":"PHASE1","title":"A First in Human Study in Healthy Volunteers and in Participants With Frontotemporal Dementia With Granulin (GRN) Mutation","status":"COMPLETED","sponsor":"Alector Inc.","startDate":"2018-09-14","conditions":"Healthy, Frontotemporal Dementia","enrollment":64}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":21,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"AL-001","genericName":"AL-001","companyName":"Beijing Anlong Biopharmaceutical Co., Ltd.","companyId":"beijing-anlong-biopharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AL-001 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}